Annovis Bio, Inc. (ANVS)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Maria L. Maccecchini Ph.D.
|
Founder, Acting CFO, CEO, President & Executive Director | 808k | -- | 1951 |
|
Dr. Cheng Fang Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Ms. Eve M. Damiano M.S., RAC
|
Senior Vice President of Regulatory Operations | -- | -- | -- |
|
Mr. Blake Jensen M.B.A.
|
Head of Quality | -- | -- | -- |
|
Ms. Hilda Maibach
|
Senior Vice President of Statistics | -- | -- | -- |
Annovis Bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 7
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
